MPM BIOVENTURES 2018, L.P. sold $616K of TRDA (indirect holdings)
MPM BIOVENTURES 2018, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership but is unlikely to affect market perception significantly.
Market read
Small insider sale with limited price impact; primarily of interest to shareholders tracking insider activity.
What to watch
Potential upcoming corporate actions or financing needs not disclosed.
Background
Form 4 filings provide transparency on insider holdings and trades.
Ticker impact
SEC Form 4 disclosed MPM BioVentures sold 86,914 shares of Entrada Therapeutics for $615,777, reducing its stake.
Potential slight downward pressure, unlikely to move price materially.
Sale amount is under $1M and represents a small percentage of holdings; market impact limited.
Market effects
Minimal effect on biotech sector; typical insider transaction.
None
Low
Counterpoint
Insider may be reallocating capital, not necessarily negative for the company.
Key entities
- CompanyEntrada Therapeutics, Inc.
Biotech firm listed on NASDAQ under ticker TRDA.
- InvestorMPM BioVentures 2018, L.P.
Insider reporting a 10% ownership stake.
